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Abstract
Sporadic or idiopathic Parkinson's disease (PD) is an age-related neurodegenerative disorder of 
unknown origin that ranks only second behind Alzheimer's disease (AD) in prevalence and its 
consequent social and economic burden. PD neuropathology is characterized by a selective loss of 
dopaminergic neurons in the substantia nigra pars compacta; however, more widespread 
involvement of other CNS structures and peripheral tissues now is widely documented. The onset 
of molecular and cellular neuropathology of PD likely occurs decades before the onset of the 
motor symptoms characteristic of PD. The hallmark symptoms of PD, resting tremors, rigidity and 
postural disabilities, are related to dopamine (DA) deficiency. Current therapies treat these 
symptoms by replacing or boosting existing DA. All current interventions have limited therapeutic 
benefit for disease progression because damage likely has progressed over an estimated period of 
~5 to 15 years to a loss of 60%–80% of the nigral DA neurons, before symptoms emerge. There is 
no accepted definitive biomarker of PD. An urgent need exists to develop early diagnostic 
biomarkers for two reasons: (1) to intervene at the onset of disease and (2) to monitor the progress 
of therapeutic interventions that may slow or stop the course of the disease. In the context of 
disease development, one of the promises of personalized medicine is the ability to predict, on an 
individual basis, factors contributing to the susceptibility for the development of a given disease. 
Recent advances in our understanding of genetic factors underlying or contributing to PD offer the 
potential for monitoring susceptibility biomarkers that can be used to identify at-risk individuals 
and possibly prevent the onset of disease through treatment. Finally, the exposome concept is new 
in the biomarker discovery arena and it is suggested as a way to move forward in identifying 
biomarkers of neurological diseases. It is a two-stage scheme involving a first stage of exposome-
wide association studies (EWAS) to profile omic features in serum to discover molecular 
biomarkers. The second stage involves application of this knowledge base in follow-up studies. 
This strategy is unique in that it promotes the use of data-driven (omic) strategies in interrogating 
diseased and healthy populations and encourages a movement away from using only reductionist 
strategies to discover biomarkers of exposure and disease. In this short review we will examine 1) 
advances in our understanding of the molecular mechanisms underlying PD that have led to 
candidate biomarkers for diagnosis and treatment efficacy and 2) new technologies on the horizon 
that will lead to novel approaches in biomarker development.
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1. Introduction
Parkinson's disease, which is the second most common neurodegenerative disorder after 
Alzheimer's disease, has a late onset and is diagnosed in about 1% of individuals over the 
age of 65. PD is an incurable and progressive disorder that gradually robs the individual of 
motor control. Traditionally, PD has been considered an idiopathic or sporadic disease 
characterized pathologically by the degeneration and loss of the dopaminergic neurons in the 
nigral striatal pathway and the presence of Lewy pathology [1]. The diagnosis of PD usually 
is clinical and an autopsy is considered necessary for disease confirmation. No validated 
diagnostic biomarker of PD is available. Unfortunately, the cardinal and defining motor 
symptoms (Parkinsonism) used in the clinical diagnosis of PD also occur in other disorders, 
but not all of these clinical “look-a-likes” have a neurodegenerative component. In 
idiopathic PD, these cardinal features, which are not apparent until a great deal of 
degeneration has already occurred, include body tremors, slowed movement, muscle 
rigidity, and an irregular posture, but more recently non-motor extra-nigral symptoms also 
have been recognized [1,2]. PD is not just a complex motor disorder but now is considered a 
systemic disease as its non-motor symptoms often precede the clinical motor signs. These 
include olfactory and autonomic dysfunction (e.g., constipation), as well as sleep and 
cognitive disturbances; their presence in most patients suggests that they could be used as 
prodromal/pre-clinical markers of PD [3–5]. The lack of motor symptoms during the early 
disease stage may be due to “neuronal reserve” or active compensatory mechanism(s) (e.g., 
collateral axonal sprouting from surviving DA neurons) [6]. Early in the disease the 
diagnostic error rate can be as high as 25% among practitioners with limited clinical 
experience in PD. This high level of misdiagnosis affirms the strong need for a diagnostic 
biomarker of PD. A suitable biomarker would allow treatment with putative neuroprotective 
agents to begin long before the significant and irreversible loss of neurons, and would enable 
the assessment of disease modification in individuals receiving treatments.
1.1. The need for several types of PD biomarkers
The Biomarkers Definitions Working Group [7] has defined a biomarker as “a characteristic 
that is objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes or pharmacological responses to a therapeutic intervention”. No 
presently available biomarker able can predict the onset of PD or constitutes a definite 
diagnostic test. Misdiagnosis often occurs early in the disease and an autopsy is needed to 
confirm diagnosis. The difficulties in diagnosing PD make the search for biomarkers 
difficult as identifying the diagnostic criteria for a disease is an important step in beginning 
to identify and validate biomarkers. Since the clinical diagnosis of PD usually occurs only 
after a substantial number of SN neurons have degenerated, there is a need for PD 
biomarkers that include (1) prodromal, preclinical or premotor stage biomarkers;(2) 
biomarkers of risk or susceptibility; and (3) motor stage biomarkers (Fig. 1) [8,9]. 
Biomarkers addressing these categories could be based on clinical, imaging, genetic, 
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proteomic, or biochemical factors or various combinations of these [2]. A sole reliance on a 
clinical assessment to identify PD subjects impedes research progress and even seasoned 
clinicians make diagnostic errors early in the disease. This is seen in the ELLDOPA, 
CALM-PD and REAL-PET studies where imaging analyses found no evidence of striatal 
dopaminergic deficits in some subjects diagnosed as having early PD based on clinical signs 
[10]. Further, progression and treatment response are mostly determined using semi 
quantitative subjective clinical scales like the UPDRS that focus almost exclusively on the 
motor symptoms. The reliance on clinical diagnosis and the ensuing problems have 
instigated a call to conceptualize PD differently and change the criteria for the diagnosis and 
staging of PD by using, for example, a tier approach in research efforts. Even the use of 
pathologic findings as the final judge in diagnosis is being questioned. For example, 
pathology can be inconclusive in genetic forms of PD [11–14]. Additional criteria that could 
involve, for example, non-motor clinical signs like anosmia, would not replace the existing 
clinical criteria. Rather, they would supplement them to better stratify subjects in research 
efforts as well as in clinical trials involving treatment and neuroprotective agents. However, 
some of these schemes are criticized for their failure to include the core DA deficit of PD or 
address the issue of false positives [15].
Obvious problems are inherent in PD diagnosis and there is a great need for reliable and 
cost-effective biomarkers of PD. Adhering to the broad definition described above, a wide 
range of candidate measurements has been evaluated, including olfactory testing, tissue and 
fluid analysis, functional neuroimaging, and genetic susceptibility. Future diagnosis of PD is 
likely to involve multiple indices including clinical, laboratory, imaging and genetics [16–
18]. The best and most useful biomarker(s) would be sensitive, reproducible, and technically 
feasible for most labs, inexpensive, noninvasive and most important, thoroughly validated 
[19].
1.2. Types of biomarkers and their purpose
Prodromal or premotor biomarkers would be diagnostic biomarkers and would identify PD 
before a significant degree of damage has occurred and at a stage when neuroprotective 
therapies could halt or slow neuronal loss. Risk biomarkers are needed to identify cohorts 
with a high probability of developing clinical PD. Premotor symptoms may reflect 
pathogenic processes in the development of PD, and understanding them may have 
etiological implications [20]. Motor stage biomarkers would serve to chart disease 
progression and aid in determining the efficacy of various therapies given in the period 
when motor symptoms are readily apparent due to the marked degeneration of SN neurons. 
An obvious goal would be the identification of prodromal biomarkers early in the disease. 
Although it is widely acknowledged that prodromal, motor stage and other biomarkers of 
PD are needed, there has been limited progress despite an intensive investment of time and 
effort. This failure could be a consequence of the strategies used to identify biomarkers of 
PD that involve an intensive characterization of specimens from individuals already 
diagnosed and that are in the late stages of PD. Some failures may be due to issues 
concerning the lack of strict sample collection under specific PD diagnostic criteria, 
resulting in poor sample quality as well as the inappropriate storage of what would have 
been high quality specimens [21,22]. The Parkinson's Progression Markers Initiative 
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(PPMI), which involves 20 centers in the USA and Europe, aims to combat this problem by 
enrolling equal numbers of early stage (before medication) PD patients and matched 
controls [23]. All involved centers will adhere to standardized techniques for repeated 
biosampling (blood, CSF, urine), clinical assessments and imaging. Strict standards for 
sample archiving, storage and analysis also are part of the initiative. NINDS has followed 
suit with its Parkinson's Disease Biomarkers Program emphasizing cooperation and 
collaboration between consortium members, a sample repository and a Data Management 
Resource.
1.3. Strategies for biomarker discovery
A number of different strategies have been utilized in the search for PD biomarkers. Many 
efforts have relied on an extensive characterization of those diagnosed with PD. Such efforts 
have added to the current knowledge concerning the molecular neuropathology of PD and 
identified possible targets for neuroprotection and development of viable preclinical animal 
models of PD. They also have identified functional and imaging changes accompanying 
disease progression as well as the possible contribution of genetics. Biomarkers emanating 
from the characterization of the molecular neuropathology of PD would be considered 
pathogenesis-based (e.g., biomarkers based on mitochondrial dysfunction) (Fig. 2). A newer, 
less restricted approach, an exposome strategy, encourages a more expansive and less 
reductionist strategy with less of an emphasis on single candidate biomarkers [4,24]. Below 
we will provide a brief synopsis of the current molecular characterization of PD. Genetic, 
functional, fluid and tissue, as well as imaging biomarkers will be discussed. Finally, we 
will examine the conceptual and methodological barriers to the development of useful PD 
biomarkers and how newer discovery approaches may move the field forward.
1.4. Molecular neuropathology of PD
As already noted, PD is a disease characterized by the loss of pigmented DA neurons in the 
SN accompanied by the cardinal motor symptoms of bradykinesia, tremor at rest, rigidity, 
and postural instability. Considerable effort has been directed at using post-mortem tissue to 
investigate the molecular neuropathology accompanying these defining characteristics [25]. 
It is believed that determining and characterizing the molecular underpinnings of PD will 
lead to early biomarkers of PD as well as viable treatments for preventing or halting it. 
These investigational studies have focused on the pathological hallmarks of PD, namely (1) 
the degeneration and death of the melanin containing neurons of the SN, and (2) Lewy 
pathology — the presence of intra-cytoplasmic Lewy bodies with inclusions containing 
mainly α-synuclein and ubiquitin. Neuronal projections, called Lewy neurites, containing 
similar inclusions also are present.
Naturally, these investigations have focused on cell death mechanisms as the DA containing 
neurons of the SN die. The presence of nuclear TUNEL labeling and chromatin 
condensation in PD brains suggests that these SN neurons may suffer a programmed cell 
death (i.e., apoptosis). Further examination of PD brains identified changes in mitochondrial 
function, increased oxidative stress, lysosomal dysfunction, protein aggregation and 
impaired degradation, deposition of iron as well as inflammation and glial activation. All of 
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these observations suggest target areas to be explored for potential biomarkers and 
development of useful animal models of PD [26].
Many failed PD neuroprotection clinical trials have been based on the putative mechanisms 
discussed above, such as those accounting for the neuronal loss (e.g., apoptosis, 
mitochrondrial dysfunction). These “cause-directed” trials involved antioxidants, trophic 
factors, and enhancers of mitochondrial function, agents to block excitotoxicity or apoptosis. 
To date no disease modifying or neuroprotective treatments have been identified. This 
failure likely is due to an incomplete understanding of the multiple pathogenic elements of 
PD, a lack of validated biomarkers of the stages of PD and its progression, a lack of target 
engagement by the test agent, due to an ineffective dose or failure to reach the site, or an 
incorrect assessment of clinical state due to concurrent administration of agents providing 
symptomatic relief. If multiple mechanisms are involved, then targeting one pathway is 
likely to be ineffective. It is also important to note that disease modification can occur 
without altering neuronal loss; a test agent may merely ameliorate symptoms giving the 
appearance of neuroprotection [27–29].
1.5. Genetic biomarkers
Although having a family member with PD is a risk factor, for many years genetics was not 
considered to have much of an influence on susceptibility to PD because of its late onset and 
the sporadic nature of the idiopathic form. Idiopathic PD now is considered to have a 
complex etiology involving multiple influences including lifestyle, genetics, and 
environment. Investigations involving associations between single nucleotide 
polymorphisms in many candidate genes (e.g. ones related to detoxification like CYPs or 
DA) and PD risk have shown no relationship or only weak ones [30–32]. To date, genome 
wide association surveys (GWAS) have identified 16 PD loci but these explain only a small 
percentage of the heritability. However, the discovery of rare, early onset familial forms 
engendered a belated recognition of the possible importance of genetics in that these forms 
can be caused by a variety of mutations in a single gene (Fig. 2). For example, point 
mutations, duplications, and triplication in the SNCA gene cause PD with high penetrance 
and interestingly some SNPs of this gene appear related to risk [8,33]. Accordingly, 
characterizing the monogenetic autosomal dominant forms of PD has identified genes and 
gene products (Fig. 2) that may be critical for determining the underlying cause(s) of the 
pathology in PD. These efforts have focused attention on mitochondrial dysfunction and 
mutations in mitochondrial genes (e.g., SNCA) and gene products (α-synuclein). Many of 
the gene products of the mutated genes in the autosomal dominant forms have been linked to 
oxidative stress, mitochondrial dysfunction and mishandling of impaired or aberrant forms 
of the gene products (e.g, oligometric α-synuclein) [19]. Further, these proteins because of 
their intimate association with disease pathophysiology (e.g., α-synuclein) have been 
identified as candidate biomarkers for PD.
1.6. Fluid and tissue biomarkers of PD — α-synuclein as an example
The identification and development of useful biomarkers for neurodegenerative diseases 
have been hindered by the limited access to diseased brain tissue until death and autopsy. 
Further hampering the efforts is the fact that most patients do not go to autopsy. As there is 
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no barrier between CSF and the brain this fluid is considered to be ideal to interrogate for 
biomarkers of neurodegenerative diseases. However, CSF is not as easily accessed as other 
body fluids such as blood and urine, whose collection, unlike CSF, is considered almost 
non-invasive. Consequently efforts are intensifying in determining the potential benefits of 
using these convenient fluids to screen for PD biomarkers. Although a variety of candidates 
related to aspects of PD pathology have been evaluated for their suitability as fluid 
biomarkers (e.g., neurofilaments, neurotransmitters, urate, DJ-1), to date α-synuclein is 
probably one of the most investigated, for several reasons [4,34]. For example, Lewy 
pathology, a hallmark of PD, is found in the brain tissue of PD patients and consists of 
neurons and neurites containing inclusions of misfolded and aggregated α-synuclein. Also, 
α-synuclein is the protein product of the SNCA gene; its mutation causes one of the 
monogenetic forms of PD, further strengthening the rationale for investigating its potential 
as a PD biomarker [34]. α-synuclein in its native, aggregated and putative pathological 
(oligomeric, phosphorylated) forms has been found in a variety of tissues from both living 
and deceased PD patients including CSF, blood, urine, saliva, gastrointestinal tract, vagus 
nerve, sympathetic and stellate ganglia, cutaneous autonomic nerves, and submandibular 
gland. As some of these tissues are easily accessed in living patients (e.g., colon) and there 
is at present no tissue biopsy test for PD, they may be useful for developing such a test 
[19,35–39].
It should be noted that there are technical and methodological issues associated with the 
collection and storage of the fluids evaluated for biomarker content that may contribute to 
the high degree of variability in fluid biomarkers (e.g., location of the needle insert for CSF) 
observed between collection centers. For certain proteins like a-synuclein and DJ-1 the 
levels in blood are much higher than in CSF suggesting that blood contamination of CSF 
may be a serious issue [40,41]. A standardization of procedures would help to reduce or 
eliminate these problems.
1.7. Imaging and other functional biomarkers of PD
1.7.1. Imaging—Neuroimaging using single-photon emission tomography (SPECT), 
positron emission tomography (PET), magnetic resonance imaging (MRI) and transcranial 
sonography (TCS) can provide important information on brain structure and function in PD 
and serve as an adjunct to clinical assessment. As these approaches are non-invasive they 
can repeatedly assess the integrity of the DA system and provide anatomical profiles (e.g., 
asymmetry of uptake, etc), as well as information about the time frame of neuron loss. In 
some instances they are correlated with disease severity. All, with the exception of TCS, are 
expensive, limiting their usefulness in standard diagnostic situations [2,42–44]. MRI, 
functional MRI, SPECT, PET as well as transcranial sonography all have been used in 
efforts to differentiate PD from other movement disorders and can facilitate diagnostic 
accuracy. Transcranial sonography can detect an echo of greater density in midbrain with 
good accuracy in PD patients in both hospital-based and community settings. This midbrain 
hyperechogenicity may reflect increased iron content in the SN of PD patients even early in 
disease, although 10% of controls also show a heightened signal. Although, TCS is cost-
effective and has shown promise as a possible imaging biomarker in PD, it is very 
dependent on operator skill, is not specific and requires an adequate temporal acoustic bone 
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window for good imaging. Also, the size of the echogenic signal is not related to PD 
duration nor do longitudinal studies show an increased signal with disease progression. 
Thus, the usefulness of TCS may be limited to differential diagnosis in the early disease 
stage especially when combined with other prodromal signs like anosmia. Voxel-based 
morphometry techniques can reveal structural similarities and volume differences that aid in 
differentiating between PD and other motor disorders in the early stages of the diseases 
where misdiagnosis is more prevalent [45,46].
1.8. Functional/behavioral indices
Early non-motor symptoms of PD are believed to reflect degeneration in extra-nigral areas 
before the loss of DA nigral neurons and include disturbances in olfaction, sleep, visuo-
spatial abilities, cognition including diminished executive function as well as changes in 
behavior [11]. Functional tests aimed at these symptoms may indicate PD risk, are 
noninvasive and may be cost effective, are usually easy to administer and include some 
evaluations which can be done at home and/or on-line by participants themselves. These 
include olfaction acuity tests (e.g., the University of Pennsylvania Smell Identification Test 
— the UPSIT), the REM sleep behavior disorder screening questionnaire, a keyboard 
tapping test, the bradykinesia akinesia incoordination test (BRAIN), and accelerometer 
based exams. These tests have been used in several studies (e.g., PREDICT-PD) and have 
shown promise for the eventual development of screening programs for PD risk that can be 
used in community settings or at a population level. The test scores can be used alone or 
along with other risk factors (e.g., age) to develop risk algorithms [47–50]. Although these 
approaches show promise at identifying risk their real utility will not be known until they 
have been validated. There is a need to know which if any of these pre-motor features will 
have a predictive time course, change in an orderly fashion, or predict the individuals who 
will develop PD. Many of these features are not specific to PD. There are also ethical 
considerations associated with both false positive and negative outcomes. Would the 
knowledge be beneficial considering there are no treatments to halt the neurodegeneration? 
Would benefits outweigh the needless worry caused by a false positive diagnosis (see 
[18,20,47] for a discussion of the issues and caveats)?
1.9. The future — new approaches in disease biomarker discovery
In many diseases, not just PD, the search for biomarkers has been driven by an extensive 
investigation and characterization of the disease itself as well as diseased tissue. In PD, the 
examination of post-mortem brain tissue has led to the identification of relevant molecular 
pathways and genes that have allowed for targeted therapies, development of animal models, 
and new drug delivery systems [8,26,51–53]. These targeted strategies have identified many 
biomarker candidates that are being actively evaluated in various tissue compartments for 
their potential as different types of PD biomarkers (e.g, α-synuclein) [19,25,34,38,54].
Newer approaches espouse casting a broader net and utilizing more global non-targeted 
strategies, such as omics (e.g., genomics, proteomics, metabolomics, etc.), for identifying 
multiple biomarkers in tissue from healthy and diseased individuals [4,16,24,55,56]. For 
example, a metabolomics evaluation of plasma generated a set of metabolites (i.e., a 
signature) able to differentiate PD patients from controls irrespective of medication status. 
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Recent work using CSF and serum from deceased PD patients with a complete pathological 
assessment shows that the profiling of these cell-free peripheral fluids provides a true 
reflection of the cellular pathological changes in the diseased tissue [57]. These positive 
results suggest that the use of platforms that more easily identify groups of analytes that 
differ between disease and control subjects may advance the search for biomarkers of PD 
more quickly (however, see [41] for more of a tempered view of large-scale molecular 
profiling approaches). Despite the enthusiastic acceptance of the technological advances and 
the collection of multiple large data sets, these approaches have not yet produced any useful 
clinical biomarkers of PD. The promise of these approaches may yet come to fruition with a 
greater attention to standardization of clinical assessment and appropriate stratification of 
study subjects, as well as the standardized and appropriate collection and storage of 
biosamples.
Finally, future efforts should be directed towards the interrogation of existing data sets from 
large population based studies as well as the analysis of archived fluid and tissue samples 
from large prospective population-based cohort studies, where there has been an emphasis 
on clinical observations and repeated sample collection over a long period (e.g., 
Framingham Heart study; Honolulu Asian Aging Study, a continuation of the Honolulu 
Heart Program) [47,58]. Every effort should be made to use current bioinformatics and 
technological approaches (e.g., omics) to thoroughly evaluate these valuable commodities.
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Factors and premotor markers associated with loss of neurons (————) prior to onset of 
motor signs and clinical diagnosis (====). Adapted from [48].
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Proposed mechanisms and gene expression events underlying pathogenesis of PD. Adapted 
from [25].
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